Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jyothi Mann

Gastroenterology Greensboro, NC Medical Doctor

NPI 1881701928 CMS profile 84885

1593 Yanceyville St Bldg A, Suite 100, Greensboro, NC 27405

Open in the dashboard

General payments

$9,828

545 records reported · program years 2019–2025

Research payments

$21,566

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$433,715 paid to institutions, not to them · program years 2019–2024

Through program year 2025, Jyothi Mann of Greensboro, NC is reported in the CMS Open Payments database as having received $9,828 across 545 general payments and $21,566 in research payments paid to them. Separately, studies naming them as principal investigator received $433,715 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 91st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,626 75
2024 General $1,906 93
2023 General $1,522 88
2023 Research $70 1
2022 General $2,096 126
2021 General $1,546 94
2021 Research $7,231 1
2020 General $614 37
2020 Research $13,155 2
2019 General $517 32
2019 Research $1,109 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jyothi Mann
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Jyothi Mann were reported at $1,626. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Jyothi Mann Gastroenterology median Middle half National median
2019 $517 $417 $126–$1,100 $163
2020 $614 $224 $74–$624 $114
2021 $1,546 $352 $106–$1,054 $132
2022 $2,096 $448 $129–$1,270 $149
2023 $1,522 $533 $150–$1,390 $160
2024 $1,906 $605 $160–$1,606 $164
2025 $1,626 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,965 168 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,288 86 payments
  3. Janssen Biotech, Inc. $1,105 53 payments
  4. Pfizer Inc. $656 41 payments
  5. Ardelyx, Inc. $543 27 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $383 21 payments
  7. Celgene Corporation $377 19 payments
  8. Ferring Pharmaceuticals Inc. $315 21 payments
  9. Ironwood Pharmaceuticals, Inc $311 16 payments
  10. Lilly USA, LLC $265 13 payments
  11. Other $1,621 80 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,640 541 payments
  2. Education $151 3 payments
  3. Gift $37 1 payment
Products named General payments · program years 2019–2025
  1. LINZESS $1,300 77 payments
  2. CREON $880 47 payments
  3. STELARA $875 46 payments
  4. XIFAXAN $817 58 payments
  5. RINVOQ $650 36 payments
  6. VIBERZI $619 35 payments
  7. SIMPONI ARIA $598 33 payments
  8. SIMPONI $598 33 payments
  9. XELJANZ $597 38 payments
  10. IBSRELA $543 27 payments
  11. Other $6,174 329 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Eli Lilly and Company $21,566 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

1,089

Median for Gastroenterology: 569

Drug cost

$317,125

Median for Gastroenterology: $104,976

Branded share of claims

46.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 32 $128,191
Rinvoq Upadacitinib Brand 12 $85,858
Linzess Linaclotide Brand 53 $54,647
Mesalamine Generic 35 $11,617
Dexlansoprazole Dr Dexlansoprazole Brand 30 $11,518
Famotidine Generic 164 $6,041
Clenpiq Sod Picosulf/Mag Ox/Citric Ac Brand 30 $5,111
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 249 $4,046
Omeprazole Generic 147 $2,584
Pantoprazole Sodium Generic 192 $2,541

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$30,989

Medicare's payments for the services billed

Medicare patients

229

Average age 72

Services billed

378

163 women, 66 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 47%
Diabetes 30%
Ischemic heart disease 27%
Depression 24%
Chronic kidney disease 21%
Cancer 17%
Osteoporosis 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LINZESS
  • AbbVie, Inc. $226
  • Ironwood Pharmaceuticals, Inc $22
$248 53 —
IBSRELA
  • Ardelyx, Inc. $197
$197 — —
OMVOH
  • Lilly USA, LLC $153
$153 — —
RINVOQ
  • AbbVie, Inc. $121
$121 12 —
SKYRIZI
  • AbbVie, Inc. $100
$100 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

550 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record